Despite a Q1 Drop in Sales, J&J Anticipates New Indications Will Increase Xarelto Revenue Growth - BioSpace
Despite a Q1 Drop in Sales, J&J Anticipates New Indications Will Increase Xarelto Revenue Growth BioSpace
Life sciences giant blamed the Medicare "doughnut hole" and increased competition for the blood thinner's declining sales.
Comments
Post a Comment